<?xml version='1.0' encoding='utf-8'?>
<document id="31872603"><sentence text="[Pharmacokinetics of active ingredients of Pudilan Xiaoyan Oral Liquid in rats and effect on liver drug-metabolizing enzymes]." /><sentence text="This study is aimed to establish a method for the determination of baicalin,baicalin and purpurin in the plasma of rats after oral administration of Pudilan Xiaoyan Oral Liquid( PDL) by using liquid chromatography-mass spectrometry( LC-MS),analyze the pharmacokinetics of three components in rats,and investigate the effects of PDL on drug-metabolizing enzymes in rat liver"><entity charOffset="67-75" id="DDI-PubMed.31872603.s2.e0" text="baicalin" /><entity charOffset="76-84" id="DDI-PubMed.31872603.s2.e1" text="baicalin" /><entity charOffset="89-97" id="DDI-PubMed.31872603.s2.e2" text="purpurin" /><pair ddi="false" e1="DDI-PubMed.31872603.s2.e0" e2="DDI-PubMed.31872603.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31872603.s2.e0" e2="DDI-PubMed.31872603.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31872603.s2.e0" e2="DDI-PubMed.31872603.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31872603.s2.e1" e2="DDI-PubMed.31872603.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31872603.s2.e1" e2="DDI-PubMed.31872603.s2.e2" /></sentence><sentence text=" C18 column was used for liquid chromatography separation,with acetonitrile-water( containing 0" /><sentence text=" 2% formic acid) as the mobile phase for gradient elution"><entity charOffset="4-15" id="DDI-PubMed.31872603.s4.e0" text="formic acid" /></sentence><sentence text=" The mass spectrometry was detected by electrospray ion source( ESI) under multi-reaction monitoring mode( MRM),as well as positive and negative ion alternating mode" /><sentence text=" Plasma sample collection was performed by using an automatic blood collection meter for small animals" /><sentence text=" The pharmacokinetic parameters were calculated by Win Nonlin software" /><sentence text=" The total protein concentration of rat liver microsomes and the total enzyme content of CYP450 were determined by BCA method and spectrophotometry respectively" /><sentence text=" The methodological study in terms of linear range,recovery rate,precision and sample stability,was used to confirm that the LC-MS analysis method established in this experiment was simple,exclusive,accurate and reliable,and can meet the requirement of determining the content of baicalin,oroxindin and corynoline in plasma after PDL administration in rats"><entity charOffset="280-288" id="DDI-PubMed.31872603.s9.e0" text="baicalin" /><entity charOffset="289-298" id="DDI-PubMed.31872603.s9.e1" text="oroxindin" /><entity charOffset="303-313" id="DDI-PubMed.31872603.s9.e2" text="corynoline" /><pair ddi="false" e1="DDI-PubMed.31872603.s9.e0" e2="DDI-PubMed.31872603.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31872603.s9.e0" e2="DDI-PubMed.31872603.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31872603.s9.e0" e2="DDI-PubMed.31872603.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31872603.s9.e1" e2="DDI-PubMed.31872603.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31872603.s9.e1" e2="DDI-PubMed.31872603.s9.e2" /></sentence><sentence text=" The drug-time curve showed that baicalin and oroxindin had a bimodal phenomenon,and the pharmacokinetic parameters indicated that baicalin,oroxindin and corynoline in PDL had certain drug-like properties"><entity charOffset="33-41" id="DDI-PubMed.31872603.s10.e0" text="baicalin" /><entity charOffset="46-55" id="DDI-PubMed.31872603.s10.e1" text="oroxindin" /><entity charOffset="131-139" id="DDI-PubMed.31872603.s10.e2" text="baicalin" /><entity charOffset="140-149" id="DDI-PubMed.31872603.s10.e3" text="oroxindin" /><entity charOffset="154-164" id="DDI-PubMed.31872603.s10.e4" text="corynoline" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e0" e2="DDI-PubMed.31872603.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e0" e2="DDI-PubMed.31872603.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e0" e2="DDI-PubMed.31872603.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e0" e2="DDI-PubMed.31872603.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e0" e2="DDI-PubMed.31872603.s10.e4" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e1" e2="DDI-PubMed.31872603.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e1" e2="DDI-PubMed.31872603.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e1" e2="DDI-PubMed.31872603.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e1" e2="DDI-PubMed.31872603.s10.e4" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e2" e2="DDI-PubMed.31872603.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e2" e2="DDI-PubMed.31872603.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e2" e2="DDI-PubMed.31872603.s10.e4" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e3" e2="DDI-PubMed.31872603.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31872603.s10.e3" e2="DDI-PubMed.31872603.s10.e4" /></sentence><sentence text=" After 7 consecutive days of PDL administration,the rat liver coefficient,total liver microparticle protein and CYP450 enzyme content were increased,but there was no significant difference,indicating that PDL was less likely to develop drug-drug interaction based on CYP enzyme" /><sentence text=" The results of this experiment can provide reference for the research on in vivo efficacy and drug interaction of PDL as well as on its clinical application" /><sentence text="" /></document>